Home Cart Sign in  
Chemical Structure| 1476-53-5 Chemical Structure| 1476-53-5

Structure of Novobiocin sodium
CAS No.: 1476-53-5

Chemical Structure| 1476-53-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Novobiocin sodium is an antibiotic that derived from Streptomyces niveus.

Synonyms: Albamycin sodium; Cathomycin sodium; Novobiocin (sodium salt)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Novobiocin sodium

CAS No. :1476-53-5
Formula : C31H35N2NaO11
M.W : 634.61
SMILES Code : CC1=C(OC2=O)C(C(O)=C2NC(C3=CC(C/C=C(C)/C)=C([O-])C=C3)=O)=CC=C1O[C@H](OC(C)(C)[C@H](OC)[C@H]4OC(N)=O)[C@@H]4O.[Na+]
Synonyms :
Albamycin sodium; Cathomycin sodium; Novobiocin (sodium salt)
MDL No. :MFCD00066541

Safety of Novobiocin sodium

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280

Related Pathways of Novobiocin sodium

DNA

Isoform Comparison

Biological Activity

Target
  • Topo II

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF7 breast cancer cells 0.17 ± 0.07 μM (IC50) 72 hours To determine the anti-proliferative activity of compound 2 against MCF7 breast cancer cells PMC5444390
A549 lung cancer cells 0.15 ± 0.02 μM (IC50) 72 hours To determine the anti-proliferative activity of compound 2 against A549 lung cancer cells PMC5444390
SKBr3 breast cancer cells ~700 µM exhibits anti-tumor activity through Hsp90 inhibition PMC3164572
SKBr3 breast cancer cells ~700 μM To determine the IC50 value of Novobiocin against SKBr3 breast cancer cells PMC5444390

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02099240 Osteomyelitis Early Phase 1 Recruiting September 2019 United States, Kentucky ... More >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.58mL

0.32mL

0.16mL

7.88mL

1.58mL

0.79mL

15.76mL

3.15mL

1.58mL

References

[1]Yun BG, Huang W, et al. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. Biochemistry. 2004 Jun 29;43(25):8217-29.

[2]Marcu MG, Chadli A, et al. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem. 2000 Nov 24;275(47):37181-6.

[3]May JM, Owens TW, Mandler MD, Simpson BW, Lazarus MB, Sherman DJ, Davis RM, Okuda S, Massefski W, Ruiz N, Kahne D. The Antibiotic Novobiocin Binds and Activates the ATPase That Powers Lipopolysaccharide Transport. J Am Chem Soc. 2017 Dec 6;139(48):17221-17224

[4]Mandler MD, Baidin V, Lee J, Pahil KS, Owens TW, Kahne D. Novobiocin Enhances Polymyxin Activity by Stimulating Lipopolysaccharide Transport. J Am Chem Soc. 2018 Jun 6;140(22):6749-6753

[5]Rodríguez-Cerrato V, Del Prado G, Huelves L, Naves P, Ruiz V, García E, Ponte C, Soriano F. Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by beta-lactam-susceptible and highly resistant pneumococci. Int J Antimicrob Agents. 2010 Jun;35(6):544-9

[6]Nordenberg J, Albukrek D, Hadar T, Fux A, Wasserman L, Novogrodsky A, Sidi Y. Novobiocin-induced anti-proliferative and differentiating effects in melanoma B16. Br J Cancer. 1992 Feb;65(2):183-8

[7]Luo XG, Zou JN, Wang SZ, Zhang TC, Xi T. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells. IUBMB Life. 2010 Mar;62(3):194-9

[8]Eder JP, Teicher BA, Holden SA, Cathcart KN, Schnipper LE. Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. J Clin Invest. 1987 May;79(5):1524-8

 

Historical Records

Categories